PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy

被引：0
|
作者：
Yixiang Zhu
Ye Zhang
Xingsheng Hu
Mingzhao Wang
Hongyu Wang
Yutao Liu
机构：
[1] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Department of Medical Oncology
[2] Chinese Academy of Medical Sciences and Peking Union Medical College,Department of Radiation Oncology
[3] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,undefined
[4] Chinese Academy of Medical Sciences and Peking Union Medical College,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2022年 / 148卷
关键词：
EGFR mutation or ALK rearrangement; Brain metastasis; Immune checkpoint inhibitor (ICI); Chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3557 / 3566
页数：9
相关论文
共 50 条
  • [31] EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases
    Jiang, Tao
    Zhang, Yongchang
    Li, Xuefei
    Zhao, Chao
    Chen, Xiaoxia
    Su, Chunxia
    Ren, Shengxiang
    Yang, Nong
    Zhou, Caicun
    EUROPEAN JOURNAL OF CANCER, 2019, 121 : 98 - 108
  • [32] CNS outcomes in EGFR/ALK wild-type NSCLC patients with brain metastases treated with immune checkpoint inhibitors (ICI).
    Shultz, David Benjamin
    Lau, Sally Cm
    Poletes, Christopher
    Le, Lisa W.
    MacKay, Kate
    Shepherd, Frances A.
    Bradbury, Penelope Ann
    Leighl, Natasha B.
    Liu, Geoffrey
    Sacher, Adrian G.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review
    Nardone, Valerio
    Romeo, Caterina
    D'Ippolito, Emma
    Pastina, Pierpaolo
    D'Apolito, Maria
    Pirtoli, Luigi
    Caraglia, Michele
    Mutti, Luciano
    Bianco, Giovanna
    Falzea, Antonella Consuelo
    Giannicola, Rocco
    Giordano, Antonio
    Tagliaferri, Pierosandro
    Vinciguerra, Claudia
    Desideri, Isacco
    Loi, Mauro
    Reginelli, Alfonso
    Cappabianca, Salvatore
    Tassone, Pierfrancesco
    Correale, Pierpaolo
    RADIOLOGIA MEDICA, 2023, 128 (03): : 316 - 329
  • [34] Prolonging TKI treatment after limited progression with local therapy in ALK- or EGFR-NSCLC
    Laursen, Michael R. T.
    Nielsen, Anna M.
    Jensen, Rawia F. G.
    Andersen, Jon L.
    Persson, Gitte F.
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S1749 - S1753
  • [35] The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review
    Valerio Nardone
    Caterina Romeo
    Emma D’Ippolito
    Pierpaolo Pastina
    Maria D’Apolito
    Luigi Pirtoli
    Michele Caraglia
    Luciano Mutti
    Giovanna Bianco
    Antonella Consuelo Falzea
    Rocco Giannicola
    Antonio Giordano
    Pierosandro Tagliaferri
    Claudia Vinciguerra
    Isacco Desideri
    Mauro Loi
    Alfonso Reginelli
    Salvatore Cappabianca
    Pierfrancesco Tassone
    Pierpaolo Correale
    La radiologia medica, 2023, 128 : 316 - 329
  • [36] Benmelstobart plus anlotinib in patients with EGFR-positive advanced NSCLC after failure of EGFR TKIs therapy: a phase I/II study
    Shi, Meiqi
    Chen, Ping
    Cui, Bin
    Yao, Yuanhu
    Wang, Juanyi
    Zhou, Tong
    Wang, Li
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [37] PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?
    Gettinger, Scott
    Politi, Katerina
    CLINICAL CANCER RESEARCH, 2016, 22 (18) : 4539 - 4541
  • [38] ORA-LM: Molecular Analysis in Cerebrospinal Fluid of ALK or EGFR Positive NSCLC Patients with Leptomeningeal Metastases
    van der Wel, T.
    Boelens, M. C.
    Jebbink, M.
    Smulders, S. A.
    Tiemessen, M. A.
    Maas, K. W.
    Luitse, M. J.
    Compter, A.
    Boltjes, R. P. B.
    Sol, N.
    Monkhorst, K.
    van den Broek, D.
    Smit, E. F.
    de langen, A. J.
    Brandsma, D.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S354 - S355
  • [39] Catechol estrogen profiles of patients with EGFR- and ALK-positive non-small cell lung cancer (NSCLC)
    Bodor, J. Nicholas
    Treat, Joseph
    Krzizike, Daniel D.
    Zawislak, Carolyn L.
    Vanderveer, Lisa
    Eidbo, Sarah
    Ross, Eric A.
    Edelman, Martin J.
    Andrews, Andrew J.
    Clapper, Margie L.
    CANCER RESEARCH, 2022, 82 (12)
  • [40] Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment
    Bordi, Paola
    Tiseo, Marcello
    Rofi, Eleonora
    Petrini, Iacopo
    Restante, Giuliana
    Danesi, Romano
    Del Re, Marzia
    CLINICAL LUNG CANCER, 2017, 18 (06) : 692 - 697
12345